NPR3 and esophageal cancer: Clinically, NPRA serves as a prognostic biomarker in gastric/esophageal cancers, while NPRC agonists (e.g., C-ANP4-23) and NPRB-targeting dCNP show promising antitumor efficacy in preclinical models.